Background: Genome-wide association studies are widely used to map genomic regions contributing to lung cancer (LC) susceptibility, but they typically do not identify the precise disease-causing genes/variants. To unveil the inherited genetic variants that cause LC, we performed focused exome-sequencing analyses on genes located in 121 genome-wide association study-identified loci previously implicated in the risk of LC, chronic obstructive pulmonary disease, pulmonary function level, and smoking behavior.
Introduction
Although almost 80% of lung cancers (LCs) are attributed to smoking, LC develops in only about 15% of smokers. Therefore, it remains of great importance to understand the genetic factors that contribute to LC risk. It is well recognized that tobacco-induced chronic obstructive pulmonary disease (COPD) is an important predictor of LC risk. Genome-wide association studies (GWASs) have identified 45 genome-wide significant loci for LC, 22 loci for COPD, 32 loci for smoking behavior (SM), and 63 loci for pulmonary function (PF) levels, totaling 121 unique susceptibility loci (Supplementary  Table 1 ). Interestingly, there is considerable overlap among these susceptibility loci and genes for these phenotypes (LC, COPD, SM, and PF levels). For example, the 6p21-22, 15q24-25.1, and 19q13.2 regions are shared by all four phenotypes; 5p15.33, 6p21.32, 10q23.31, and 10q25 are shared by three phenotypes; and 15 loci shared by two phenotypes (see Supplementary Table 1) .
Although GWASs have been successful in identifying common (minor allele frequency [MAF] >5%) variants of small effect, the overall amount of LC heritability explained by these known common variants remains small. Further, because the tag single-nucleotide polymorphisms (SNPs) utilized in GWASs are used to identify genomic regions of interest rather than being selected for causality, identification of the functional variant at a specific locus generally poses a significant challenge. For example, of the 93 common LC GWAS top hits from the 45 reported susceptibility loci, 1 only two are protein coding (cholinergic receptor nicotinic alpha 3 subunit gene (CHRNA3) p.Tyr215 and cholinergic receptor nicotinic alpha 5 subunit gene (CHRNA5) p.Asp398Asn), with the remaining 91 variants falling in noncoding regions (four in untranslated regions, seven in flanking regions, 70 in intron regions, and 10 in intergenic regions). Alleles that are functionally deleterious will tend to be underrepresented at high frequencies, which is an assertion that is supported by the observation of a relationship between putative functionality and MAF. Recent studies suggest that multiple low-frequency (1% < MAF < 5%) or rare (MAF <1%) variants exhibit stronger effect sizes (ORs) than common variants do and contribute to the missing heritability. 2 Supporting this hypothesis is the observation that several genes containing known low-frequency or rare variants with moderate to large effect are associated with LC (e.g., poly(A) 5 To unveil the inherited germline rare variants, we used whole exome sequencing with a focused analysis of the known 121 high-priority GWAS susceptibility loci (260 potential target genes). Smoking, family history of LC, and COPD are all well-documented risk factors for LC. To efficiently identify the most probable causative variants and genes, we have sequenced selected case patients with extreme phenotypes (high-risk patients with familial LC and sporadic patients reporting a history of heavy smoking and or severe COPD) and controls who report a history of heavy smoking but have normal spirometry results and are considered resistant to the effects of smoking.
Methods

Study Population in Discovery
Case patients with LC were derived from four independent case series, including sporadic cases from Baylor College of Medicine (BCM) (n ¼ 68), [6] [7] [8] Harvard School of Public Health (n ¼ 101), and M. D. Anderson Cancer Center (n ¼ 37) and familial cases from the Genetic Epidemiology of LC Consortium (n ¼ 54) (each familial case was chosen from one family considered at high risk of LC and having three or more affected firstdegree members). 5, 9 All case patients were white and had histologically confirmed NSCLC. Patient clinical and demographic information, such as smoking history (status and pack-years [PY]), was obtained by using selfadministered questionnaires. For sporadic patients with LC, moderate-to-severe COPD phenotype was carefully defined by PF tests (reduced forced expiratory volume in 1 second [FEV 1 ] <80% predicted, and ratio of FEV 1 to forced vital capacity [FEV 1 /FVC] <0.7). COPD phenotyping data were not available for familial cases.
The smoking controls were selected from two independent studies: (1) the Genetic Epidemiology of COPD Study (n ¼ 298), which included 10,192 current or former smokers and which was a multicenter investigation to examine the genetic epidemiology of COPD and smoking-related lung diseases, 10 and (2) the BCM COPD and LC study (n ¼ 20), which enrolled current or former smokers and was launched in 2002 within the Texas Medical Center in Houston, Texas. [6] [7] [8] All subjects underwent study-related testing that included spirometry, computed tomography scans of the chest, and blood collection. The controls were white, resistant smokers with normal PF data (defined as postbronchodilator FEV 1 !80% predicted and FEV 1 /FVC !0.7) and at least a 10-PY history of smoking cigarettes. DNA was isolated from peripheral blood or saliva both from patients with LC and from controls. The study was approved by the institutional review boards of all sites accruing participants and by the institutional review board at BCM for exome sequencing conducted at the Human Genome Sequencing Center (HGSC).
Library Preparation, Capture Enrichment, and Exome Sequencing DNA samples were constructed into Illumina pairedend precapture libraries (Illumina, San Diego, CA) according to the manufacturer's protocol. The complete library and capture protocol, as well as the oligonucleotide sequences, have been described in detail previously. 11, 12 For exome capture, each library pool was hybridized in solution to the BCM-HGSC-designed VCRome 2.1 probe set (Roche NimbleGen, Madison, WI) according to the manufacturer's protocol. This exome capture probe set targets the Vertebrate Genome Annotation, Consensus Coding Sequence Project, and RefSeq gene models, with 45.2 megabase capture targeting 23,585 genes. Exome sequencing was performed in paired-end mode with use of the Illumina HiSeq 2000 platform (Illumina). Sequencing runs generated approximately 300 to 400 million successful reads on each lane of a flow cell, yielding 7 to 13 gigabases per sample. For exome sequencing yields, samples achieved an average depth of coverage of 200Â over exonic regions. Sequence analysis was performed by using the BCM-HGSC Mercury analysis pipeline. 13 All sequence reads were mapped to the GRCh37 human reference genome by using the BurrowsWheeler aligner.
14 Putative variants, including singlenucleotide variants (SNVs) and insertions or deletions (indels), were called by using the Atlas2 suite. 15 Read qualities were recalibrated with the Genome Analysis Toolkit, and a minimum quality score of 30 was required; also, the variant must have been present in more than 15% of the reads that cover the position.
Single-Rare Variant Filtering and Functional Annotation
Our analysis was restricted to mapping of rare variants within the exonic regions of the 121 known GWAS loci (see Supplementary Table 1 for genomic coordinates and 260 target genes). Variants were annotated for effect on the protein and predicted function by using the SNP and Variation Suite (SVS, Golden Helix, Inc, Bozeman, MT). To identify pathogenic variants, a three-step filtering protocol was designed; it used automated filtering followed by manual review (Fig. 1) . In step 1, automated filtering identified variants that fulfilled the following criteria: (1) mutation type, including missense and disruptive (defined as nonsense, stop-gain/loss, splice site destructions, and frameshift indels, which severely disrupt protein structure); (2) mutation effects (i.e., the variant was predicted to result in truncation of the protein or was predicted to be damaging/deleterious [not to be benign/tolerated] to the protein with use of the sorting intolerant from tolerant, PolyPhen-2, Mutation taster and scaled C-scores from the Combined Annotation-Dependent Depletion [CADD] method, 16 which strongly correlates with both molecular functionality and pathogenicity); and (3) MAF less than 1% in the Europeans in the reference databases, including the Exome Aggregation Consortium (ExAC), 1000 Genomes Project (1KGP), UK10K project, and UCSC Common SNPs tracks. Novel variants were defined as never having been reported in a publicly available database and the University of California Santa Cruz All SNPs 135/ 137/141 tracks. In step 2, after implementation of the aforementioned automated filtering schema, manual review of the raw BAM files were performed by using the GenomeBrowse (Golden Helix, Inc). This filter was used to remove the false-positive events that result from mapping errors and mutations found in a "noisy" background (multiple mismatches or indels in flanking sequences). These highly rare and predicted deleterious mutations were used to perform the gene-based burden analysis. In step 3, we further prioritized candidate variants that were highly enriched in the case patient group (risk alleles) or the control group (protective alleles).
Gene-Based Burden Analysis of Multiple Rare Deleterious Variants
To have greater power to detect significant associations with rare variants, we performed gene-based collapsing tests for those genes that included two or more rare and predicted deleterious variants (from filtering steps 1 and 2), including the combined multivariate and collapsing (CMC) test and the kernel-based adaptive cluster (KBAC) test. 17, 18 To measure their cumulative effect, the CMC first bins variants according to MAF criterion (thresholds at 1%, 0.1%, and 0.01%) based on the observed data, then collapses the multiple variants within each bin, and finally uses Hotelling's T 2 to perform multivariate testing on the counts across the various bins. The KBAC test first counts multimarker genotypes within a given gene based on the variant data and then performs a special case-control test based on the weighted sum of these allele counts. To account for multiple comparisons, we calculated the false discovery rate (FDR)-adjusted p values. 19 
Study Population in Validation
To discover robust associations and validate the promising candidates, we analyzed two independent sets. The first was the Wayne State University (WSU) study, which enrolled participants at Karmanos Cancer Institute or Henry Ford Health System. Study participants either underwent spirometry or had PF test data abstracted from their medical records. 20 We carefully selected case patients with LC and a smoking history of at least 10 PY and smoking controls with normal PF (FEV 1 !80% predicted, and FEV 1 /FVC !0.7) and a smoking history of at least 10 PY. Genotyping was performed by using the Illumina MEGA panel (Illumina), which includes more than 1.7 million variants. The second of the two independent sets was the Transdisciplinary Research in Cancer of the Lung Team of the 
Allelic Association Analysis in the Combined Data Sets
We then tabulated the minor allele and reference allele counts per candidate in the combined discovery and validation data sets and performed allelic association analysis, which compares frequencies of alleles in case patients with LC cases controls, and in case patients with LC versus in the ExAC reference population (nonFinnish Europeans [N ¼ 33,370]). We note that the individuals in the reference set are not necessarily healthy-many have adult-onset diseases, such as type 2 diabetes and schizophrenia. Because the numbers of mutation carriers are small (fewer than 5), Fisher's exact tests were used for the allelic association analysis. ORs, 95% confidence intervals (CIs) and FDR-adjusted p values were calculated.
Results
Demographic and clinical information including age, sex, smoking history, histologic type, and PF data are summarized in Table 1 . The discovery set included 260 cases of patients with LC (54 familial and 206 sporadic cases); in 75 of the 206 sporadic cases, patients also had moderate-to-severe COPD. In all, there were 318 smoking controls with a smoking history of 15 or more PY and normal PF data. The validation populations (WSU and TRICL-ILCCO populations) included 1773 case patients and 1123 controls. Among the combined 2033 case patients and 1441 controls of European descent, 129 case patients (6%) and 303 controls (21%) were nonsmokers, mostly from the TRICL-ILCCO study. In terms of smoking intensity (mean PY value), in the discovery, lower PY values were reported in the case patients with LC than in the controls (mean 46 versus 54 [P < 0.001]), whereas much higher PY values were reported in case patients than in controls in the two validation studies (mean 52 versus 35 in the WSU study, and 43 versus 23 in the TRICL-ILCCO study, respectively [both P < 0.001]). Regarding LC histologic type, adenocarcinoma was the most common type across the three data sets, with 52% in the discovery set and 51% and 44% in the two validation sets, respectively.
Analysis of Recurrent Rare and Deleterious Variants
In the discovery set, of 99,489 SNVs and 1206 indels mapped in the exons of the target 121 known loci (260 genes), 1446 were functional mutation types (1411 nonsynonymous SNVs, 10 splice sites, 16 stop gain/loss, and nine frameshifts), of which 432 were rare and 168 were further predicted to be potential deleterious. Our stepwise filtering strategy ( Fig. 1 and Table 2 ) identified 48 recurrent candidate variants of which 30 were highly enriched in patients with LC (risk-conferring) and 18 enriched in controls (protective), including three stopgains, three splice-sites, and 42 nonsynonymous SNVs. These 48 candidates were located in 33 genes at 25 of the risk loci and presented in a total of 68 smoking controls and 85 patients (17 familial and 68 sporadic cases; eight sporadic carriers had severe COPD, of whom 70% had the adenocarcinoma histologic type). Among the candidates carriers, 13 (two with familial and 11 with sporadic cases, none of whom had severe COPD) and eight controls were multicarriers who had carried at least two candidates (Supplementary Table 2 ). It is interesting to note that four of the 13 multicarrier patients had p.Gly337Glu in zinc finger protein 93 gene (ZNF93) (Online Mendelian Inheritance in Man [OMIM] No. 603975). In particular, one patient with adenocarcinoma (age 60 years, male sex, and smoking history of 30 PY) was a carrier of four candidates, including two candidates from ZNF93. For the controls, six of eight multicarriers carried one or two candidates from disheveled-associated activator of morphogenesis 2 gene (DAAM2) (OMIM No. 606627).
In the validation sets, of the 48 candidates, five (10%) were not covered by both validation studies. Specifically, 15 (31%) were not covered by the WSU study, whereas six (13%) were not covered in the TRICL-ILCCO study. As shown in Table 3 , the top most risk-conferring variant from the allelic association analysis is a known stop codon, p.Lys3326X (K3326X) in BRCA2 (OMIM No. 600185). This stop gain results from an A > T transversion in the 27 th exon that leads to the loss of the final 93 amino acids of the BRCA2, DNA repair associated gene protein (UniProt No. P51587). The MAF of K3326X in the case patients was significantly higher than in the . This truncating variant had the highest scaled CADD C-score of 38 and was predicted to be in the top 0.1% most deleterious substitutions in the human genome. The K3326X occurred in the highly conserved COOH-terminal domain, which plays a critical role in the homologydirected repair of DNA double-strand breaks.
Another two top candidates were missense variants, p.Leu87Phe in lymphotoxin beta gene (LTB) (OMIM No. 600978) and p.Gln185His in prolyl 3-hydroxylase 2 gene (P3H2) (also known as LEPREL1) (OMIM No. 610341). Both variants were carried by only one control (MAF 0.034%) but occurred in 11 and eight cases (MAF 0.27% and 0.19%), respectively, with an effect size of 7.52 (95% CI: 1.01-16.56) and 5.39 (95% CI: 0.75-15.43), respectively. Likewise, these two variants were exceedingly rare in the ExAC reference population (MAF 0.09% and 0.06, respectively), and they were predicted to be among the 1% most deleterious (CADD scores of 23 and 27, respectively). The LTB p.Leu87Phe occurred at the third exon of the gene and a remarkably conserved bstrand structure that links the transmembrane and tumor necrosis factor domains of the protein (UniProt No. Q06643 [ Fig. 2A]) . The P3H2 p.Gln185His is located in the second exon of the gene and between the second and third tetratricopeptide-like helical repeats of the protein (UniProt No. Q8IVL5 [Fig. 2B]) .
In contrast to the aforementioned three riskconferring variants, we also identified one protective variant, p.Asp762Gly in DAAM2. The LC risk for carriers of DAAM2 p.Asp762Gly decreased fourfold compared with that for the study controls (OR ¼ 0.25, 95% CI: 0.10-0.79) and threefold compared with that for the ExAC population (OR ¼ 0.34, 95% CI: 0.11-0.94). The p.Asp762Gly is located in the 18th exon of the gene, which is close to two acetylation sites, Lys765 and Lys766, and lies in the second formin homology domain of the protein (UniProt No. Q86T65 [Fig. 2C] ). In the same gene, another candidate, p.Arg172His, although not statistically significant, was also enriched in controls, with an MAF of 0.45% in smoker controls and 0.31% in the ExAC reference population, compared with 0.22% for case patients.
Other promising candidates with consistent allelic associations include p.Gly337Glu in ZNF93, p.Ala66Pro in C-type lectin family 3 member A gene (CLEC3A) (OMIM No. 613588), and a splice acceptor (rs201402002) in bromodomain containing 9 gene (BDR9). Unfortunately, these three variants were not covered in the WSU study. In addition, five SNVs showed suggestive evidence (only significant in LC case versus in the ExAC population): mitochondrial intermediate peptidase gene (MIPEP) p.Leu197Pro, regulator of telemere elongation helicase (RTEL1) p.Gln397Glu, phospholipase C epsilon 1 gene (PLCE1) p.Thr467Ile, syntrophin gamma 1 gene [(SNTG1) p.Val121Leu, and ZNF93 p.Lys388Asn (see Table 3 ). 
Gene-Based Burden Analysis of Rare Variants
Discussion
Despite previous family-based linkage studies and intensive population-based GWAS analyses and candidate gene screening, a large proportion of the heritability of LC remains unexplained. Our focused analyses led to identification of four rare and deleterious inherited variants associated with LC susceptibility, including one wellestablished truncating variant (BRCA2 K3326X) and three newly identified missense variations (LTB p.Leu87Phe, P3H2 p.Gln185His, and DAAM2 p.Asp762Gly). It should be noted that none of the candidate rare variants that we have identified in the present study were in linkage disequilibrium with the known LC-GWAS common SNPs. The limits of linkage disequilibrium between common and rare variants were quantified by Wray 21 and supported by previous studies. 22, 23 This study confirms a robust association between a known rare truncating variant, K3326X in 13q13.1 BRCA2, and risk of LC. The effect size in the current study (OR ¼ 2.36) is nearly identical to the previously identified association with risk of squamous cell LC (OR ¼ 2.47) 4 and upper aerodigestive tract cancer (OR ¼ 2.53), 24 and it far exceeds the small increase in risk of breast and ovarian cancer (OR ¼ 1.26). 25, 26 The molecular mechanisms that underpin this finding are unknown. In relation to the effect on cellular and biochemical properties of this variant, cancer cell lines show that mice and cells with the exon 27 truncated protein are hypersensitive to ionizing radiation 27 and cross-linking agents 28, 29 and exhibited increased susceptibility to various types of solid tumors. 30 It has been demonstrated that patients who have ovarian cancer and BRCA1/BRCA2 germline mutations respond favorably to poly(ADP-ribose) polymerase 1 inhibitors in clinical trials. [31] [32] [33] Therefore, it is possible that patients who have LC with BRCA2 K3326X may also similarly respond favorably to poly(ADP-ribose) polymerase inhibition and benefit from treatment.
An interesting finding is the association with the immunity-related gene LTB, which is localized to the 6p21.33 major histocompatibility complex region (which has been previously implicated in risk of LC, COPD, SM, and PF levels). [34] [35] [36] [37] Functional studies in gene knockout and transgenic mouse systems have shown that LTB is of fundamental importance in fibrogenesis and carcinogenesis because of its action through a distinct receptor lymphotoxin beta receptor and nuclear factor kappa B. 38 The lymphotoxin beta protein plays a key role in innate immunity and inflammation, which have been the focus of intensive basic science and translational research. 39 Another finding in the chromosome 6p region was the protective effects of DAAM2. This 6p21.2 region is a known susceptibility loci to multiple diseases including PF levels, 34 smoking cessation, 40 renal cancer, 41 schizophrenia, 42 and hypospadias. 43 The DAAM2 gene is involved in the regulation of actin cytoskeleton in several different tissues, including the tissue of the tracheal airways system, 44 and it is abnormally regulated in nasopharyngeal carcinoma 45 and COPD. 46 The dishevelled associated activator of morphogenesis 2 protein is one of the key WNT/plantar cell polarity signaling pathway proteins and has been documented to promote oncogenesis, stem cell renewal, and tumor proliferation. 47, 48 The 3q28 P3H2 plays a critical role in collagen metabolic processes and oxidation reduction, and it inhibits cell proliferation. 49 Previous work has shown that P3H2 genes are novel targets for epigenetic silencing in breast cancer. 50 The pathogenic mutation p.Gly508Val was associated with high degree myopia. [51] [52] [53] Moreover, from the TISSUES the database, P3H2 expression shows the highest levels in lung tissue. 54 A main strengths of this study are the accurate PF data and smoking exposure data. In the discovery set, in which only a small number of individuals were exome sequenced, the inclusion of even a small proportion of misclassified individuals could have affected the analysis. On the other hand, extreme phenotypes increase statistical power. Our discovery set (260 cases) included the 102 cases from our previous study 5 , 48 sporadic cases in which patients reported histories of heavy smoking and severe COPD, and 54 familial cases in which patients were likely enriched for disease-associated genetic signals. In the WSU validation study, the smoking controls were strictly selected in terms of normal PF despite a history of heavy smoking, and thus, they were considered to be resistant to the effects of smoking; in contrast, for the LC cases, there were only 75 sporadic LC cases in which patients had severe COPD and in which the tobacco exposure would be considered quite substantial. It should be noted however that our study is still underpowered for the association analysis of each rare variant in a limited number of 2033 cases and 1441 controls. Although the association of CCDC147 p.Arg696Cys and DBH p.Val26Met between the case patients with LC and the ExAC reference population did not attain statistical significance, our result is in line with the results of our previous work. 5 Another limitation is that we have focused on missense, nonsense, stop-gain/ loss, splice sites, and frameshift variants in our variant filtration strategies and we have not evaluated certain classes of variants, such as large gene-disrupting duplications and noncoding variants (such as flanking intronic and untranslated regions that may disrupt gene expression). Although larger studies and/or whole genome sequencing analysis might identify more rare variants with deleterious effects, the paucity of findings of recurrent rare variants impacting LC risk is intriguing.
In conclusion, our results provide evidence that the rare deleterious germline variants BRCA2 p.Lys3326X, LTB p.Leu87Phe, P3H2 p.Gln185His, and DAAM2 p.Asp762Gly contribute to LC susceptibility. However, further in-depth functional follow-up studies are still needed to evaluate the pathogenicity of each of the strong candidates reported in this study.
